

EUROPEAN RESPIRATORY MONOGRAPH

Volume 11  
Monograph 35, April 2006

# Cystic Fibrosis

Edited by  
A.K. Webb and F.A. Ratjen



EUROPEAN  
RESPIRATORY  
SOCIETY

# **Cystic Fibrosis**

European Respiratory Monograph 35  
April 2006

Editor in Chief  
K. Larsson

This book is one in a series of European Respiratory Monographs. Each individual issue provides a comprehensive overview of one specific clinical area of respiratory health, communicating information about the most advanced techniques and systems needed to investigate it. It provides factual and useful scientific detail, drawing on specific case studies and looking into the diagnosis and management of individual patients. Previously published titles in this series are listed at the back of this book with details of how they can be purchased.

# Cystic Fibrosis

Edited by  
A.K. Webb and F.A. Ratjen



European Respiratory  
Society

Published by European Respiratory Society Journals Ltd ©2006

April 2006

Hardback ISBN: 1-904097-58-8

Paperback ISBN: 1-904097-59-6

ISSN: 1025-448x

Printed by The Charlesworth Group, Wakefield, UK

Business matters (enquiries, advertisement bookings) should be addressed to: European Respiratory Society Journals Ltd, Publications Office, Suite 2.4, Hutton's Building, 146 West Street, Sheffield, S1 4ES, UK. Fax: 44 114 2780501.

All material is copyright to European Respiratory Society Journals Ltd. It may not be reproduced in any way including electronic means without the express permission of the company.

Statements in the volume reflect the views of the authors, and not necessarily those of the European Respiratory Society, editors or publishers.

**CONTENTS**

<b>The Guest Editors</b>	<b>vi</b>
<b>Preface</b>	<b>vii</b>
<b>Introduction</b>	<b>viii</b>
<b>1. New insights into the pathophysiology of lung disease in cystic fibrosis patients</b> G. Döring	<b>1</b>
<b>2. Small airways disease in cystic fibrosis</b> K.G. Brownlee	<b>21</b>
<b>3. Atypical cystic fibrosis</b> K.W. Southern	<b>38</b>
<b>4. Disease modifier genes in cystic fibrosis</b> H. Grasemann	<b>50</b>
<b>5. Emerging pathogens in cystic fibrosis</b> N. Høiby, T. Pressler	<b>66</b>
<b>6. Gene therapy for cystic fibrosis: successes and challenges</b> J.C. Davies, E.W.F.W. Alton	<b>79</b>
<b>7. Cystic fibrosis transmembrane conductance regulator pharmacotherapy</b> L.J.V. Galietta	<b>88</b>
<b>8. Cystic fibrosis infection with clonal strains of <i>Pseudomonas aeruginosa</i>: current knowledge and future management</b> A.M. Jones, S.C. Bell	<b>105</b>
<b>9. Noninvasive ventilation cystic fibrosis</b> B. Fauroux	<b>127</b>
<b>10. Difficult issues in the selection of cystic fibrosis patients for lung transplantation</b> P.A. Corris	<b>139</b>
<b>11. Diagnosis and management of cystic fibrosis related low bone mineral density</b> C.S. Haworth, S.L. Elkin	<b>150</b>

## Previously published in the European Respiratory Monograph Series:

- Pulmonary Manifestations of Systemic Diseases, Monograph 34**  
*Edited by G M Verleden, M G Demedts, R Westhovens, M Thomer (2005)*
- Diagnosis, Prevention and Treatment of Exercise-Related Asthma, Respiratory and Allergic Disorders in Sports, Monograph 33**  
*Edited by K-H Carlsen, L Delgado, S Del Giacco (2005)*
- Sarcoidosis, Monograph 32**  
*Edited by M Drent, U Costabel (2005)*
- Lung Function Testing, Monograph 31**  
*Edited by R Gosselink, H Stam (2005)*
- Imaging, Monograph 30**  
*Edited by A Bankier, P A Gevenosis (2004)*
- Surgery for Non-Neoplastic Disorders of the Chest: a Clinical Update, Monograph 29**  
*Edited by G M Verleden, D Van Raemdonck, T Lerut, M Demedts (2004)*
- Antibiotics and the Lung, Monograph 28**  
*Edited by M Cazzola, F Blasi, S Ewig (2004)*
- Pulmonary Vascular Pathology: A Clinical Update, Monograph 27**  
*Edited by M Demedts, M Delcroix, R Verhaeghe, G M Verleden (2004)*
- Lung Transplantation, Monograph 26**  
*Edited by J Boe, M Estenne, W Weder (2003)*
- Respiratory Diseases in Women, Monograph 25**  
*Edited by C Mapp, S Buist (2003)*
- Nutrition and Metabolism in Respiratory Disease, Monograph 24**  
*Edited by J Boe, M Estenne, W Weder (2003)*
- Asthma, Monograph 23**  
*Edited by F Chung, L M Fabbri (2003)*
- Pleural Diseases, Monograph 22**  
*Edited by R Loddenkemper, V B Antony (2002)*
- The Impact of Air Pollution on Respiratory Health, Monograph 21**  
*Edited by G D'Amato, S T Holgate (2002)*
- ARDS, Monograph 20**  
*Edited by T W Evans, M J D Griffiths, B F Keogh (2002)*
- Growing up with Lung Disease: The Lung in Transition to Adult Life, Monograph 19**  
*Edited by A Bush, K-H Carlsen, M S Zach (2002)*
- The Nose and Lung Diseases, Monograph 18**  
*Edited by B Wallaert, P Chanex, P Godard (2001)*
- Lung Cancer, Monograph 17**  
*Edited by S G Spiro (2001)*
- Noninvasive Mechanical Ventilation, Monograph 16**  
*Edited by J-F Muir, N Ambrosino, A K Simonds (2001)*
- Interstitial Lung Diseases, Monograph 14**  
*Edited by D Olivieri, R M du Bois (2000)*
- Pulmonary Rehabilitation, Monograph 13**  
*Edited by C F Donner, M Decramer (2000)*
- Respiratory Mechanics, Monograph 12**  
*Edited by J Milic-Emili (1999)*
- Occupational Lung Disorders, Monograph 11**  
*Edited by C E Mapp (1999)*
- Respiratory Disorders During Sleep, Monograph 10**  
*Edited by W T McNicholas (1998)*
- Pulmonary Endoscopy, Monograph 9**  
*Edited by J Strausz (1998)*
- Mechanical Ventilation from Intensive Care to Home Care, Monograph 8**  
*Edited by C Roussos (1998)*
- Management of COPD, Monograph 7**  
*Edited by D S Postma, N M Siafakas (1998)*
- Clinical Exercise Testing, Monograph 6**  
*Edited by J Roca, B J Whipp (1997)*
- New Diagnostic Techniques in Paediatric Respiratory Medicine, Monograph 5**  
*Edited by M Zach, K H Carlsen, J O Warner, F H Sennhauser (1997)*

### Monographs may be purchased from:

Publications Sales Department, Maney Publishing, Hudson Road, Leeds LS9 7DL, UK.

Tel: 44 (0)113 2497481; Fax: 44 (0)113 2486983; E-mail: books@maney.co.uk

Customers in the Americas should contact: Old City Publishing Inc., 628 North 2nd Street, Philadelphia PA 19123, USA. Tel: 1 215 925 4390; Fax: 1 215 925 4371; E-mail: info@oldcitypublishing.com

# EUROPEAN RESPIRATORY MONOGRAPH

## Instructions to Authors

The European Respiratory Monograph is an official publication of the European Respiratory Society, which publishes "state of the art" review articles, only by invitation, under the coordination of a Guest Editor(s). All manuscripts should be sent in electronic format to: [monograph@ersj.org.uk](mailto:monograph@ersj.org.uk)

Offers or queries regarding future content should be directed to the Editor in Chief: K. Larsson, Unit of Lung and Allergy Research, Division of Physiology, National Institute of Environmental Medicine, IMM, SE17177 Stockholm, Sweden. Fax: 46 8300619. E-mail: [Kjell.Larsson@ki.se](mailto:Kjell.Larsson@ki.se)

### INSTRUCTIONS FOR THE PREPARATION OF MANUSCRIPTS

#### **Presentation**

The manuscript should be accompanied by a presentation letter and a title page, with the name of the authors and their affiliation, the full mailing address, fax number and e-mail address of the corresponding author, and any source of support. A short running head should be given and not more than 6 keywords. The length of a chapter, in typescript form, should be approximately 20–30 pages of double-spaced type including text, figures, tables and references.

#### **Text**

Experimental paper format is not required, and should not include sections on methods, results and discussion. Headings and subheadings should be used to facilitate the readers. The Monograph aims to be educational. Clear distinction should be made between strong information (*i.e.* based on random, controlled clinical trials) and soft information (*i.e.* suggestive but inconclusive data). The text should start with an introduction and finish with a 10–15 line conclusion. A brief summary (no more than 300 words) is required with the typescript which should recapitulate the key points, rather than introducing the subjects to be discussed.

#### **Tables and illustrations**

Please include all tables and figures with your typescript. Each chapter must include at least one table or illustration. Every table and illustration must be cited in the text. The source of reproduction must be acknowledged (from [Ref. No.] with permission). See copyright information below.

#### **Tables**

Each table should be typed on a separate page and should have a short title. Other information should appear as footnotes to the table, indicated by superscript symbols. Large tables are difficult to read and print, and should be avoided.

#### **Illustrations**

Where a figure can replace or reduce a text passage, the figure is preferred. Figures should be named and numbered. Line drawings can be supplied as .jpeg, .gif, .tif or .btm, and will be redrawn into house style. All photographic images should be provided with a minimum of 300 dots per inch (dpi) and should preferably be supplied in .jpeg, .tif or .eps format. Photomicrographs must have internal scale markers (linear scale). Please provide a clear legend for each figure which should be brief and nonrepetitive of information given in the text, all abbreviations should be expanded in the legend.

#### **References**

The author is free to decide on how many references he/she will use. References to original work are preferred to references or quotations from other chapters in the Monograph. However, the author is free to decide on what he/she will quote. Number references consecutively in the order in which they are first mentioned in the text, including those mentioned in tables and figures. Type the references in square brackets. Cite personal communications and unpublished work in the text only, giving the name and initials of the authors and the year of writing. Follow the style of the *European Respiratory Journal* (Vancouver style).

#### **Copyright**

You must obtain from the copyright holder (usually the publisher of the work) permission to reproduce figures, tables and extended quotations. The source of any such reproduction must always be acknowledged. **The original document should be included with your manuscript to the Editor in Chief.**

For any further details please refer to the instructions to the authors of the *European Respiratory Journal*.



# Preface

He was one of three frail siblings with recurrent diarrhoea, weight loss and a feeble apparition. A boy who, during childhood and adolescence, was not able to compete with other children of his own age and who was unable to take walks due to respiratory symptoms. He suffered from recurrent respiratory infections, haemoptysis and fevers and got frequent abdominal pain and diarrhoea after eating, in particular fatty pork meals. A man who, before the age of 35, was not able to climb the stairs due to dyspnoea and weakness and who spent most of his latter years spent bedridden with characteristic tiredness, dyspnoea and difficulties with sputum expectoration, until his death in 1849 at the age of 39 yrs. He was a composer and a pianist and his name was Frederic Chopin.

It seems highly likely that Chopin suffered and died from cystic fibrosis CF and not tuberculosis as has been claimed. CF is a disease that was unknown during the nineteenth century. Although it was already asserted in German folklore that "a child who tastes salty on being kissed has a poor prognosis" CF became recognised as a disease in the first half of the 1930s, when it was distinguished from celiac disease. In 1945 mucus secretion abnormalities were described and the term mucoviscidosis was suggested. Further development included characterisation of high sweat levels of sodium and chloride and in the 1960s it was established that CF was an autosomal, recessive, inherited disease. Approximately 20 yrs after this the gene responsible for the disease was located on chromosome seven.

When CF was first described the disease was found to be affecting children who died as a result of it within the first few years of their life. However, it became clear that the CF phenotype differs between individuals and this may, in parallel with improved treatment, explain why certain affected individuals appear to have a more beneficial prognosis with prolonged survival. The knowledge regarding CF has increased tremendously during the previous decades. It is now clear that the disease is caused by a mutation in the gene coding for CF transmembrane conductance regulator, an ion channel responsible for chlorine transport in epithelial cells. The treatment has improved substantially and life-time expectancy has increased from approximately 6 months to 30 yrs. Treatment of airway infections and obstructions, nutritional repletion, anti-inflammatory therapy and lung transplantation have contributed to improve survival outcomes with the possibility of gene therapy soon becoming a probable option.

In the present issue of the European Respiratory Monograph current knowledge regarding CF has been acquired by authors who are true specialists in the field. Most aspects of CF have been covered and this Monograph will be an inestimable source of information for pulmonary physicians and scientists within the field.

**K. Larsson**  
Editor in Chief

## INTRODUCTION

Cystic Fibrosis (CF) is a lethal disease affecting children, adolescents and mature adults. However, over the past three decades, as a direct consequence of the application of multidisciplinary care delivered by CF centres worldwide, the disease has changed from one of childhood killer into prolonged adult survival.

The basic defect in CF affects all ductal systems of the body and is truly a disease with multiple systemic manifestations. As patients with CF have grown older many unexpected complications have emerged from Pandora's box to further complicate the lives of CF patients and test the management skills of clinicians. Scientific research into this disease has flourished as demonstrated by the increasing number of sessions devoted to this area at respiratory meetings in Europe and North America.

It is, therefore, timely that the *European Respiratory Journal* is publishing a *Monograph* devoted exclusively to CF. The editors have recruited recognised leaders to write about cutting edge topics of interest both to clinicians and scientists in this field. We are grateful to the authors who have produced superb reviews of their various areas of expertise. We invite all those either with an interest or who want to know more about this fascinating disease to read these reviews and use them as a source of reference and a continuing learning curve.